A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Public ClinicalTrials.gov record NCT07190248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
Study identification
- NCT ID
- NCT07190248
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 675 participants
Conditions and interventions
Conditions
Interventions
- Calderasib Drug
- Carboplatin Drug
- Cisplatin Drug
- Pembrolizumab (+) Berahyaluronidase alfa Biological
- Pemetrexed Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2025
- Primary completion
- Dec 6, 2029
- Completion
- Aug 5, 2032
- Last update posted
- May 3, 2026
2025 – 2032
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research ( Site 0108) | Birmingham | Alabama | 35209 | Recruiting |
| Stamford Hospital ( Site 0126) | Stamford | Connecticut | 06902 | Recruiting |
| Mount Sinai Cancer Center ( Site 0137) | Miami Beach | Florida | 33140 | Completed |
| Indiana University Health Arnett Cancer Center ( Site 0116) | Lafayette | Indiana | 47904 | Recruiting |
| New England Cancer Specialists ( Site 0139) | Westbrook | Maine | 04092 | Recruiting |
| New York Oncology Hematology, P.C. ( Site 0119) | Albany | New York | 12206 | Recruiting |
| Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111) | Lancaster | Pennsylvania | 17601 | Recruiting |
| Blue Ridge Cancer Care ( Site 0144) | Roanoke | Virginia | 24014 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07190248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07190248 live on ClinicalTrials.gov.